These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9462271)

  • 21. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM; Franke FE; Müller KM
    Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
    Ordóñez NG
    Mod Pathol; 2013 Aug; 26(8):1132-43. PubMed ID: 23503645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
    Chu AY; Litzky LA; Pasha TL; Acs G; Zhang PJ
    Mod Pathol; 2005 Jan; 18(1):105-10. PubMed ID: 15389250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
    Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
    Lung; 1995; 173(2):79-87. PubMed ID: 7536281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
    Edwards C; Oates J
    J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J; Lamerz R; Permanetter W
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pleural carcinosis in renal cell cancer or pleural mesothelioma? A contribution to differential diagnosis].
    Reissig A; Kriegsmann J; Fleck M; Berghäuser K; Kosmehl H; Raabe G
    Z Arztl Fortbild (Jena); 1992 Nov; 86(21):1059-66. PubMed ID: 1462668
    [No Abstract]   [Full Text] [Related]  

  • 38. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical study on routinely processed cytoblock preparations.
    Kuhlmann L; Berghäuser KH; Schäffer R
    Pathol Res Pract; 1991 May; 187(4):467-71. PubMed ID: 1876528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.
    Fetsch PA; Simsir A; Abati A
    Diagn Cytopathol; 2001 Sep; 25(3):158-61. PubMed ID: 11536437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.